---
title: "Phase III data: First-line regimens for advanced NSCLC with EGFR exon 20 insertions and PD-L1+ dis"
id: "pubmed-42755291"
canonical_url: "https://medichelpline.com/clinical-feed/pubmed-42755291"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "PubMed / NCBI"
source_url: "https://pubmed.ncbi.nlm.nih.gov/42755291/"
doi: "10.1158/2159-8290.CD-NW2026-0090"
published_at: "2026-11-02T00:00:00.000Z"
evidence_level: "Journal Article"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Phase III data: First-line regimens for advanced NSCLC with EGFR exon 20 insertions and PD-L1+ dis
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/pubmed-42755291
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** PubMed / NCBI
- **Source URL:** [Original Journal Publication](https://pubmed.ncbi.nlm.nih.gov/42755291/)
- **DOI:** [10.1158/2159-8290.CD-NW2026-0090](https://doi.org/10.1158%2F2159-8290.CD-NW2026-0090)
- **Published At:** 2026-11-02T00:00:00.000Z
- **Evidence Rating:** Journal Article
## Executive GIST (TL;DR)
- Two phase III trials presented at the 2026 World Conference on Lung Cancer — PAPILLON and REZILIENT3 — evaluated first-line combination therapies targeting patients with **EGFR exon 20 insertions**. - Investigators reported that combinations including **amivantamab** and **zipalertinib** produced significantly improved **progression-free survival** versus comparator regimens in that molecular subgroup. - The study teams observed high rates of treatment crossover after progression, which the authors reported limited the ability to demonstrate a **overall survival** advantage for the amivantamab–zipalertinib strategies. - A separate phase III study, HARMONi-2, compared a bispecific antibody, **ivonescimab**, against **pembrolizumab** in patients with **PD-L1-positive** advanced NSCLC. - Data indicated that **ivonescimab** improved **overall survival** versus pembrolizumab in the trial population; the investigators concluded the agent supports standard-of-care use in China while larger global trials remain ongoing. - The abstract did not provide specific dosing regimens, sample sizes, p-values, hazard ratios, or detailed safety and toxicity tables; the source did not report these methodological or numerical specifics. - Key limitations cited in the source include high crossover rates (PAPILLON and REZILIENT3) and the need for broader global confirmation of HARMONi-2 results; regulatory status beyond China was not reported in the abstract.
## Clinical Analysis & Structured Key Points
Clipboard, Search History, and several other advanced features are temporarily unavailable. [ Skip to main page content ](https://pubmed.ncbi.nlm.nih.gov/42755291/#article-details) ![U.S. flag](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png) An official website of the United States government Here's how you know ![Dot gov](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg) **The .gov means it’s official.** Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. ![Https](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg) **The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. [ ![NIH NLM Logo](https://cdn.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg) ](https://www.ncbi.nlm.nih.gov/) [Log in](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42755291%2F) Show account info Close #### Account Logged in as: **username** * [Dashboard](https://www.ncbi.nlm.nih.gov/myncbi/) * [Publications](https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/) * [Account settings](https://www.ncbi.nlm.nih.gov/account/settings/) * [Log out](https://www.ncbi.nlm.nih.gov/account/signout/?back_url=https%3A//pubmed.ncbi.nlm.nih.gov/42755291/) [Access keys](https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys) [NCBI Homepage](https://www.ncbi.nlm.nih.gov) [MyNCBI Homepage](https://pubmed.ncbi.nlm.nih.gov/myncbi/) [Main Content](https://pubmed.ncbi.nlm.nih.gov/42755291/#maincontent) [Main Navigation](https://pubmed.ncbi.nlm.nih.gov/42755291/) [ ![pubmed logo](https://cdn.ncbi.nlm.nih.gov/pubmed/a447896c-976f-490b-b86b-2668b65114a8/core/images/pubmed-logo-blue.svg) ](https://pubmed.ncbi.nlm.nih.gov/) [ ](https://pubmed.ncbi.nlm.nih.gov/42755291/ "Show search bar") Search: [](https://pubmed.ncbi.nlm.nih.gov/42755291/ "Clear search input")Search [Advanced](https://pubmed.ncbi.nlm.nih.gov/advanced/) [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/clipboard/) [ User Guide ](https://pubmed.ncbi.nlm.nih.gov/help/) Save Email Send to * [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/42755291/) * [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42755291%2F%23open-bibliography-panel) * [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42755291%2F%23open-collections-panel) * [Citation manager](https://pubmed.ncbi.nlm.nih.gov/42755291/) Display options Display options Format Abstract PubMed PMID ## Save citation to file Format: Summary (text) PubMed PMID Abstract (text) CSV Create file Cancel ## Email citation Email address has not been verified. Go to [ My NCBI account settings ](https://account.ncbi.nlm.nih.gov/settings/) to confirm your email and then refresh this page. To: Subject: Body: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email Cancel ### Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42755291/) Add Cancel ### Add to My Bibliography * My Bibliography Unable to load your delegates due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42755291/) Add Cancel ## Your saved search Name of saved search: Search terms: [Test search terms](https://pubmed.ncbi.nlm.nih.gov/42755291/) Would you like email updates of new search results? Saved Search Alert Radio Buttons * Yes * No Email: ([change](https://www.ncbi.nlm.nih.gov/account/settings/)) Frequency: Monthly Weekly Daily Which day? The first Sunday The first Monday The first Tuesday The first Wednesday The first Thursday The first Friday The first Saturday The first day The first weekday Which day? Sunday Monday Tuesday Wednesday Thursday Friday Saturday Report format: Summary Summary (text) Abstract Abstract (text) PubMed Send at most: 1 item 5 items 10 items 20 items 50 items 100 items 200 items Send even when there aren't any new results Optional text in email: Save Cancel ## Create a file for external citation management software Create file Cancel ## Your RSS Feed Name of RSS Feed: Number of items displayed: 5 10 15 20 50 100 Create RSS Cancel RSS Link Copy ### Full text links [![Silverchair Information Systems full text link](https://cdn.ncbi.nlm.nih.gov/corehtml/query/egifs/https:--aacrjournals.org-images-pubmed-candisc_full.gif) Silverchair Information Systems ](https://aacrjournals.org/cancerdiscovery/article-lookup/doi/10.1158/2159-8290.CD-NW2026-0090 "See full text options at Silverchair Information Systems") [ Full text links ](https://pubmed.ncbi.nlm.nih.gov/42755291/) ### Actions Cite Collections Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42755291/) Add Cancel Permalink Permalink Copy Display options Display options Format Abstract PubMed PMID ### Experimental Resource Linked Discoveries ### Page navigation * [ Title & authors ](https://pubmed.ncbi.nlm.nih.gov/42755291/#heading) * [ Abstract ](https://pubmed.ncbi.nlm.nih.gov/42755291/#abstract) * [ MeSH terms ](https://pubmed.ncbi.nlm.nih.gov/42755291/#mesh-terms) * [ Substances ](https://pubmed.ncbi.nlm.nih.gov/42755291/#substances) * [ LinkOut - more resources ](https://pubmed.ncbi.nlm.nih.gov/42755291/#linkout) Title & authors Abstract MeSH terms Substances LinkOut - more resources Cancer Discov Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Cancer+Discov%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Cancer+Discov%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42755291/) . 2026 Nov 2;16(11):OF1. doi: 10.1158/2159-8290.CD-NW2026-0090. # Phase III Trials Test First-Line Options in Advanced NSCLC _No authors listed_ * PMID: **42755291** * DOI: [ 10.1158/2159-8290.CD-NW2026-0090 ](https://doi.org/10.1158/2159-8290.cd-nw2026-0090) Item in Clipboard # Phase III Trials Test First-Line Options in Advanced NSCLC _No authors listed._ Cancer Discov. 2026. Show details Display options Display options Format Abstract PubMed PMID Cancer Discov Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Cancer+Discov%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Cancer+Discov%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42755291/) . 2026 Nov 2;16(11):OF1. doi: 10.1158/2159-8290.CD-NW2026-0090. * PMID: **42755291** * DOI: [ 10.1158/2159-8290.CD-NW2026-0090 ](https://doi.org/10.1158/2159-8290.cd-nw2026-0090) Item in Clipboard Full text links Cite Display options Display options Format Abstract PubMed PMID Linked Discoveries ## Abstract Presented at the 2026 World Conference on Lung Cancer, two phase III trials-PAPILLON and REZILIENT3-established amivantamab and zipalertinib combination therapies as effective first-line strategies for advanced NSCLC with EGFR exon 20 insertions, with significantly improved progression-free survival, although high crossover rates prevented them demonstrating an overall survival benefit. Separately, HARMONi-2 showed that the bispecific antibody ivonescimab improved overall survival versus pembrolizumab in PD-L1-positive NSCLC, supporting its use as standard of care in China while larger global trials continue. ©2026 American Association for Cancer Research. [PubMed Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/) ## MeSH terms * Antibodies, Monoclonal, Humanized / therapeutic use Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Antibodies%2C+Monoclonal%2C+Humanized%2Ftherapeutic+use%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Antibodies%2C+Monoclonal%2C+Humanized) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42755291/) * Antineoplastic Combined Chemotherapy Protocols* / therapeutic use Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Antineoplastic+Combined+Chemotherapy+Protocols%2Ftherapeutic+use%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Antineoplastic+Combined+Chemotherapy+Protocols) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42755291/) * Carcinoma, Non-Small-Cell Lung* / drug therapy Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Carcinoma%2C+Non-Small-Cell+Lung%2Fdrug+therapy%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Carcinoma%2C+Non-Small-Cell+Lung) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42755291/) * Carcinoma, Non-Small-Cell Lung* / genetics Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Carcinoma%2C+Non-Small-Cell+Lung%2Fgenetics%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Carcinoma%2C+Non-Small-Cell+Lung) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42755291/) * Carcinoma, Non-Small-Cell Lung* / pathology Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Carcinoma%2C+Non-Small-Cell+Lung%2Fpathology%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Carcinoma%2C+Non-Small-Cell+Lung) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42755291/) * Clinical Trials, Phase III as Topic Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Clinical+Trials%2C+Phase+III+as+Topic%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Clinical+Trials%2C+Phase+III+as+Topic) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42755291/) * Humans Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Humans%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Humans) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42755291/) * Lung Neoplasms* / drug therapy Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Lung+Neoplasms%2Fdrug+therapy%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Lung+Neoplasms) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42755291/) * Lung Neoplasms* / genetics Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Lung+Neoplasms%2Fgenetics%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Lung+Neoplasms) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42755291/) * Lung Neoplasms* / pathology Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Lung+Neoplasms%2Fpathology%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Lung+Neoplasms) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42755291/) ## Substances * Antibodies, Monoclonal, Humanized Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Antibodies%2C+Monoclonal%2C+Humanized%22%5Bnm%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=%22Antibodies%2C+Monoclonal%2C+Humanized%22) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42755291/) ## LinkOut - more resources * ### Full Text Sources * [ Silverchair Information Systems ](https://aacrjournals.org/cancerdiscovery/article-lookup/doi/10.1158/2159-8290.CD-NW2026-0090) * ### Research Materials * [ NCI CPTC Antibody Characterization Program ](https://antibodies.cancer.gov/detail/CPTC-EGFR-12) * ### Miscellaneous * [ NCI CPTAC Assay Portal ](https://assays.cancer.gov/CPTAC-802) **Full text links** [x] [![Silverchair Information Systems full text link](https://cdn.ncbi.nlm.nih.gov/corehtml/query/egifs/https:--aacrjournals.org-images-pubmed-candisc_full.gif) Silverchair Information Systems ](https://aacrjournals.org/cancerdiscovery/article-lookup/doi/10.1158/2159-8290.CD-NW2026-0090 "See full text options at Silverchair Information Systems") [x] Cite Copy Download .nbib .nbib Format: AMA APA MLA NLM **Send To** * [Clipboard](https://pubmed.ncbi.nlm.nih.gov/42755291/) * [Email](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42755291%2F%23open-email-panel) * [Save](https://pubmed.ncbi.nlm.nih.gov/42755291/) * [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42755291%2F%23open-bibliography-panel) * [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42755291%2F%23open-collections-panel) * [Citation Manager](https://pubmed.ncbi.nlm.nih.gov/42755291/) [x] NCBI Literature Resources [MeSH](https://www.ncbi.nlm.nih.gov/mesh/) [PMC](https://www.ncbi.nlm.nih.gov/pmc/) [Bookshelf](https://www.ncbi.nlm.nih.gov/books) [Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/) The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited. Follow NCBI [ Twitter ](https://twitter.com/ncbi) [ Facebook ](https://www.facebook.com/ncbi.nlm) [ LinkedIn ](https://www.linkedin.com/company/ncbinlm) [ GitHub ](https://github.com/ncbi) [ ](https://ncbiinsights.ncbi.nlm.nih.gov/) [Connect with NLM](https://www.nlm.nih.gov/socialmedia/index.html) * [ Twitter ](https://twitter.com/NLM_NIH) * [ SM-Facebook ](https://www.facebook.com/nationallibraryofmedicine) * [ SM-Youtube ](https://www.youtube.com/user/NLMNIH) National Library of Medicine [8600 Rockville Pike Bethesda, MD 20894](https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/@38.9959508,-77.101021,17z/data=!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb:0x19156f88b27635b8!8m2!3d38.9959508!4d-77.0988323) [Web Policies](https://www.nlm.nih.gov/web_policies.html) [FOIA](https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office) [HHS Vulnerability Disclosure](https://www.hhs.gov/vulnerability-disclosure-policy/index.html) [Help](https://support.nlm.nih.gov/?pagename=pubmed%3Apubmed%3Aabstract%3ANONE) [Accessibility](https://www.nlm.nih.gov/accessibility.html) [Careers](https://www.nlm.nih.gov/careers/careers.html) * [NLM](https://www.nlm.nih.gov/) * [NIH](https://www.nih.gov/) * [HHS](https://www.hhs.gov/) * [USA.gov](https://www.usa.gov/) ![](https://pubmed.ncbi.nlm.nih.gov/stat?HTTP_REFERER=&SELF_URL=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42755291%2F&browserheight=600&browserwidth=1080&colorDepth=24&connection_effectivetype=4g&connection_type=&cookieSize=450&cookieenabled=true&is_browser_supported=true&jsevent=render&jsloadtime=&jsperf_basePage=109&jsperf_connect=13&jsperf_dns=0&jsperf_navTimingNetworkMS=695&jsperf_navTimingRedirectCount=0&jsperf_navTimingType=navigate&jsperf_navType=0&jsperf_redirectCount=0&jsperf_ttfb=572&jsrendertime=&language_code=en-US&log_category=literature&log_displayeduids=42755291&log_icons_present=true&log_op=retrieve&log_source_db=pubmed&myncbi_signed_in=false&ncbi_algorithm=&ncbi_app=pubmed&ncbi_cost_center=pubmed&ncbi_db=pubmed&ncbi_featured_srcdb=&ncbi_nwds=yes&ncbi_nwds_ver=1.2.5&ncbi_pcid=&ncbi_pdid=abstract&ncbi_phid=EF9C00017EBF90B5000036A44877DBB6.1.m_3&ncbi_program=&ncbi_timesinceload=5&ncbi_timesincenavstart=1331&ncbi_uid=42755291&pagename=pubmed%3Apubmed%3Aabstract%3ANONE&pinger_in_iframe=false&prev_phid=EF9C00017EBF90B500003490C1BB6A74.1.m_3&screenavailheight=600&screenavailwidth=1080&screenheight=600&screenwidth=1080&server=pubmed.ncbi.nlm.nih.gov&sgSource=native&sgversion=0.42.0&sgversion_hotfix=0&sgversion_major=0&sgversion_minor=42&spa_index=0)![](https://pubmed.ncbi.nlm.nih.gov/stat?browserheight=600&browserwidth=1080&colorDepth=24&connection_effectivetype=4g&connection_type=&cookieSize=450&cookieenabled=true&is_browser_supported=true&jsevent=domready&language_code=en-US&log_category=literature&log_displayeduids=42755291&log_icons_present=true&log_op=retrieve&log_source_db=pubmed&myncbi_signed_in=false&ncbi_algorithm=&ncbi_app=pubmed&ncbi_cost_center=pubmed&ncbi_db=pubmed&ncbi_featured_srcdb=&ncbi_nwds=yes&ncbi_nwds_ver=1.2.5&ncbi_pcid=&ncbi_pdid=abstract&ncbi_phid=EF9C00017EBF90B5000036A44877DBB6.1.m_3&ncbi_program=&ncbi_timesinceload=11&ncbi_timesincenavstart=1337&ncbi_uid=42755291&pagename=pubmed%3Apubmed%3Aabstract%3ANONE&pinger_in_iframe=false&screenavailheight=600&screenavailwidth=1080&screenheight=600&screenwidth=1080&server=pubmed.ncbi.nlm.nih.gov&sgSource=native&sgversion=0.42.0&sgversion_hotfix=0&sgversion_major=0&sgversion_minor=42&spa_index=0)
## Related Clinical Research

- [Reanalysis of isotope-resolved metabolomics in patient-derived lung cancer tissue: treatment- and](https://medichelpline.com/clinical-feed/medrxiv-1-treatment-and-tissue-context-specific-isotope-labeling-patterns-in-patient.md)
- [Sacituzumab tirumotecan plus pembrolizumab shows activity in PD-L1–negative NSCLC](https://medichelpline.com/clinical-feed/nature-reviews-clinical-oncology-1-sacituzumab-tirumotecan-pembrolizumab-has-efficacy-in-pd-l1-negative-nsclc.md)
- [Perioperative ivonescimab ± chemotherapy Yields High MPR in Resectable NSCLC (Phase 2)](https://medichelpline.com/clinical-feed/nature-1-perioperative-ivonescimab-with-or-without-chemotherapy-in-resectable-non-small.md)
- [Neoadjuvant durvalumab plus chemotherapy in resectable NSCLC: results from the phase 2 MDT-BRIDGE](https://medichelpline.com/clinical-feed/nature-0-neoadjuvant-durvalumab-plus-chemotherapy-in-resectable-or-borderline-resectable.md)
- [53L10 T‑cell engager tribody for immunotherapy of multiple solid tumors — Frontiers in Immunology](https://medichelpline.com/clinical-feed/frontiers-in-immunology-11-53l10-t-cell-engager-tribody-for-immunotherapy-of-multiple-solid-tumors.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.